EDITOR IN CHIEF
John Kellett (Denmark)

ASSOCIATE EDITORS
Mikkel Brabrand (Denmark)
Ettore Bartoli (Italy)
Eleni I. Boutati (Greece)
Tim Cooksley (UK)
Dan Justo (Israel)
Radovan Hojs (Slovenia)
Pier Mannuccio Mannucci (Italy)
Alberto M. Marra (Germany)
Carla Araújo Pimentel (Portugal)
Ramon Pujol (Bellvitge, Spain)
Shirley Rigby (UK)
2022 data

Just as predicted last year, submissions are slowing down after the pandemic. But still above average.
- 481 articles received (above average 300/year)
- 181 articles accepted
- 299 articles rejected

31 are desk reject vs 268 rejected after review

2023 estimate based on first 2 months 2023:
40 articles received/month. 480/year
Performance

- Fast peer-review process
- Copyediting service is offered to authors and included as a further step in the publication process (unlike all other publishers)
- Delays in the production phase are often due to authors’ resistance to pay the author publication charge (APC)
Goals scored

EJCRIM funds itself via APCs (author-paid article processing charge). The journal needs to guarantee a balanced flow of manuscripts and a reasonable rejection rate in order to be able to cover the journal handling and productions costs and still be selective.

In order to ensure the journal to continue performing a selective peer-review and prevent cost liabilities, the APC was increased to € 300 + VAT (total €366) starting from 1 September 2022.

No complaints received as yet...

Compared to the average APC in the market, EJCRIM’s APC remains almost 10 times cheaper and yet sustainable.
EJCRIM is indexed in Scopus.
And from 2022 it has been included in Scopus.
EJCRIM articles are indexed retrospectively from 2017.
Advantages of Scopus

- Articles indexed in Scopus count for career points in some European countries.
- **H-index** is based on Scopus database (includes also proceedings and reports)
- Increased audience for EJCRIM

Scientific production is indexed mostly in the following databases

<table>
<thead>
<tr>
<th>Database</th>
<th>Journals</th>
<th>Articles</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clarivate (JCR, WOS) impact factor calc.</td>
<td>11.655</td>
<td>2.200.000</td>
</tr>
<tr>
<td><strong>Scopus</strong></td>
<td>22.000</td>
<td>69.000.000</td>
</tr>
<tr>
<td>PubMed</td>
<td>5.280</td>
<td>28.000.000</td>
</tr>
<tr>
<td>Pubmedcentral</td>
<td>2.697</td>
<td>8.000.000</td>
</tr>
<tr>
<td>DOAJ (only open access Journals)</td>
<td>19.000</td>
<td>8.000.000</td>
</tr>
</tbody>
</table>

Source STM Report 2018
Website traffic in 2022

186,713  total views
70,272   unique readers
90,201   sessions

2       Page views per session on average
1.3     minutes time per session

Monthly downloads doubled:
15000 to almost 30000

Median monthly downloads
25000
Geographical origin of submitted manuscripts

**2022**

- North America: 44%
- Europe: 33%
- Asia: 18%
- Latin America: 2%
- Africa: 3%

**2021**

- Europe: 64%
- North America: 12%
- South and Central America: 2%
- Asia: 7%
- Africa: 4%
- Middle East...
And of accepted articles

<table>
<thead>
<tr>
<th>COUNTRY</th>
<th>Submitted</th>
<th>accepted</th>
<th>rejected</th>
</tr>
</thead>
<tbody>
<tr>
<td>USA</td>
<td>144</td>
<td>60</td>
<td>84</td>
</tr>
<tr>
<td>PORTUGAL</td>
<td>120</td>
<td>37</td>
<td>83</td>
</tr>
<tr>
<td>JAPAN</td>
<td>27</td>
<td>12</td>
<td>15</td>
</tr>
<tr>
<td>ITALY</td>
<td>19</td>
<td>8</td>
<td>11</td>
</tr>
<tr>
<td>BELGIUM</td>
<td>19</td>
<td>11</td>
<td>8</td>
</tr>
<tr>
<td>SPAIN</td>
<td>15</td>
<td>5</td>
<td>10</td>
</tr>
<tr>
<td>FRANCE</td>
<td>13</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>UK</td>
<td>11</td>
<td>2</td>
<td>8</td>
</tr>
<tr>
<td>QUATAR</td>
<td>10</td>
<td>3</td>
<td>7</td>
</tr>
</tbody>
</table>

[Diagram showing acceptance rates by continent: North America 44%, Europe 34%, Latin America 3%, Asia 16%, Africa 3%]
## Geographical distribution of readers

<table>
<thead>
<tr>
<th>Rank</th>
<th>Country</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>United States</td>
<td>35%</td>
</tr>
<tr>
<td>2.</td>
<td>India</td>
<td>29%</td>
</tr>
<tr>
<td>3.</td>
<td>China</td>
<td>28%</td>
</tr>
<tr>
<td>4.</td>
<td>United Kingdom</td>
<td>5%</td>
</tr>
<tr>
<td>5.</td>
<td>Japan</td>
<td>5%</td>
</tr>
<tr>
<td>6.</td>
<td>Portugal</td>
<td>3%</td>
</tr>
<tr>
<td>7.</td>
<td>Canada</td>
<td>3%</td>
</tr>
<tr>
<td>8.</td>
<td>Italy</td>
<td>3%</td>
</tr>
<tr>
<td>9.</td>
<td>Germany</td>
<td>3%</td>
</tr>
<tr>
<td>10.</td>
<td>France</td>
<td>3%</td>
</tr>
</tbody>
</table>

European audience is weak except for UK and Portugal.

![Pie chart showing geographical distribution of readers]
The official journal of EFIM member societies

Downward trend of European authors and readers of EJCRIM continues, with the exception of Portugal.

Only 2 out of 36 EFIM members report or mention the journal in their website:
- Finnish Society
- Portuguese Society

Portugal represents by far the top submitter and second European reader of EJCRIM in Europe.

Some easy ways in which the link can be mutually beneficial for visibility:

- National societies are encouraged to display EJCRIM on their website, link and be linked by the EJCRIM journal.
- Societies may display on their website/social a collection or a feed of the latest EJCRIM articles published from their country, increasing traffic to their website and reinforcing their community spirit.
<table>
<thead>
<tr>
<th>Rank</th>
<th>Article Title</th>
<th>Authors</th>
<th>Views</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Is Persistent Thick Copious Mucus a Long-Term Symptom of COVID-19? (2020)</td>
<td>Manckoundia et al.</td>
<td>27896</td>
</tr>
<tr>
<td>2</td>
<td>The Very First Change of the Tongue with the Development of Cancer (2017)</td>
<td>Hamada et al.</td>
<td>21659</td>
</tr>
<tr>
<td>3</td>
<td>Is Persistent Thick Copious Mucus a Long-Term Symptom of COVID-19? (2020)</td>
<td>Manckoundia et al.</td>
<td>27896</td>
</tr>
<tr>
<td>5</td>
<td>Giant Basal Cell Carcinoma of the Shoulder with Spontaneous Bleeding: A Successful Surgical Approach (2021)</td>
<td>Oliveira et al.</td>
<td>4319</td>
</tr>
<tr>
<td>6</td>
<td>Acute Epiglottitis Due to COVID-19 Infection (2021)</td>
<td>Emberey et al.</td>
<td>3890</td>
</tr>
</tbody>
</table>
Some observations

• Interest in and usage of EJCRIM case reports lasts longer than for other types of journal articles in journals that do not publish case reports.

• Articles of 2015-2017 are still downloaded a lot

• The average usage of 2021 and 2022 case reports is approx 3500 views
What do we have in store for 2023?

• A collaboration with EFIM Academy: our authors could be selected for a talk for the Home of Medicine Podcast and also invited to contribute to the same academy with their content

• EJCRIM Best Case Report Competition at ECIM 2023

• ECIM 2023 Abstract Book (after the Congress)

Social media?

The plan to promote EFIM’s and both journals’ content to the European Internal medicine community as one voice and share the cost of a social media editor has not been implemented. It was envisaged as an opportunity to build a strong European Internal Medicine community based on scientific content.
Get in touch with us if you wish to collaborate and/or share ideas!

info@ejcrim.com
And citations!

3334 total citations*

Of which

2231 citations from articles published 2020-2022
+404 citations from June 2022

*Citations are counted from Google Scholar, from the launch of the journal in 2014